PGx mavacamten
Mavacamten is a cardiac myosin inhibitor for the treatment of symptomatic (NYHA class II to III) hypertrophic obstructive cardiomyopathy. It is metabolised mainly by the polymorphic enzyme CYP2C19, whose no-function alleles *2 and *3 abolish enzyme activity. This analysis determines a patient’s CYP2C19 metaboliser status, because poor metabolisers can have up to threefold higher mavacamten exposure and an increased risk of systolic dysfunction. The EU product information requires CYP2C19 genotyping before treatment.
Indication | ICD-10 | Gene | OMIM |
| Adverse drug reaction | T88.7 | CYP2C19 | 124020 |
Created by
Our editorial team consists of medical specialists and scientists in the field of human genetics. All content is created and reviewed in accordance with current scientific standards.
Last content review: August 4, 2026. As pharmacogenomic evidence and recommendations continue to evolve, the information presented on this page may not always reflect the latest updates. For current guidance and annotations, please refer to .
Are you a patient?


Certified laboratories

